Parexel Names Dr. Sy Pretorius Chief Scientific Officer
Parexel International named Dr. Sy Pretorius its Chief Scientific Officer. Dr. Pretorius currently serves as the Company’s Corporate Vice President and Worldwide Head of Early Phase, and will continue in that capacity in addition to assuming his expanded responsibilities.
As Chief Scientific Officer, Dr. Pretorius will enhance and lead innovation of clinical research methodologies, and help PAREXEL further integrate its offerings to meet growing industry demand for end-to-end drug development services. He will focus on a variety of important capabilities, including clinical trial modelling and simulations, as well as adaptive trial designs. Dr. Pretorius will also lead the Company’s study optimisation services by aligning its considerable scientific and therapeutic expertise to provide valuable guidance to customers in clinical study design, with a goal of increasing study predictability while reducing costs and time to market.
Dr. Pretorius is a board-certified medical doctor with master’s degrees in Clinical Pharmacology and Business Administration. In nearly 18 years at PAREXEL, he has held positions of increasing responsibility, most recently as head of Early Phase services. He will continue to lead PAREXEL’s global Phase I and IIa services. These services are provided via the Company’s hospital-based clinical network, which spans three continents, as well as its global Proof of Concept division.
Other news from the department people
